Jefferies downgraded Prothena (PRTA) to Hold from Buy with a price target of $6, down from $32. The company’s Phase III study in light-chain amyloidosis failed for the second time, the analyst tells investors in a research note. The firm says the company will discontinue and reduce opex related to birtamimab and will have more updates in June. The next investor focus will be on PRX-012 Phase I/II for Alzheimer’s data by August, but Jefferies is cautious this will show significant efficacy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue